| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 35 | 2024 | 3000 | 2.600 |
Why?
|
| Genetic Predisposition to Disease | 27 | 2024 | 2335 | 1.800 |
Why?
|
| Germ-Line Mutation | 13 | 2023 | 344 | 1.460 |
Why?
|
| Genetic Testing | 16 | 2024 | 537 | 1.100 |
Why?
|
| Biomarkers, Tumor | 12 | 2021 | 1543 | 0.970 |
Why?
|
| BRCA2 Protein | 10 | 2024 | 161 | 0.940 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2021 | 56 | 0.890 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2019 | 152 | 0.680 |
Why?
|
| BRCA1 Protein | 8 | 2023 | 204 | 0.680 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 2411 | 0.670 |
Why?
|
| Ovarian Neoplasms | 7 | 2023 | 763 | 0.660 |
Why?
|
| Drugs, Investigational | 2 | 2016 | 36 | 0.660 |
Why?
|
| Female | 67 | 2024 | 46011 | 0.630 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 350 | 0.620 |
Why?
|
| Aged | 39 | 2024 | 19077 | 0.610 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2016 | 103 | 0.610 |
Why?
|
| Prognosis | 10 | 2024 | 3773 | 0.610 |
Why?
|
| Humans | 94 | 2024 | 89063 | 0.590 |
Why?
|
| Stroke | 2 | 2023 | 982 | 0.550 |
Why?
|
| Middle Aged | 43 | 2024 | 25863 | 0.530 |
Why?
|
| Neoplasms | 11 | 2023 | 3035 | 0.530 |
Why?
|
| Checkpoint Kinase 2 | 5 | 2023 | 26 | 0.500 |
Why?
|
| Genes, BRCA2 | 5 | 2023 | 161 | 0.490 |
Why?
|
| Drug Screening Assays, Antitumor | 5 | 2018 | 78 | 0.470 |
Why?
|
| Ultrasonography, Mammary | 4 | 2022 | 83 | 0.450 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2017 | 481 | 0.430 |
Why?
|
| Case-Control Studies | 14 | 2021 | 1855 | 0.430 |
Why?
|
| Adult | 36 | 2024 | 26507 | 0.420 |
Why?
|
| Thrombectomy | 3 | 2024 | 172 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2019 | 1265 | 0.410 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 1429 | 0.400 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 5 | 2023 | 14 | 0.390 |
Why?
|
| Recombinational DNA Repair | 2 | 2021 | 9 | 0.380 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2021 | 158 | 0.370 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 6777 | 0.370 |
Why?
|
| Microbiota | 4 | 2021 | 398 | 0.360 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 2347 | 0.340 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 666 | 0.330 |
Why?
|
| Genetic Variation | 6 | 2022 | 1371 | 0.330 |
Why?
|
| Prospective Studies | 13 | 2024 | 4273 | 0.330 |
Why?
|
| Mutation | 13 | 2021 | 4132 | 0.320 |
Why?
|
| Machine Learning | 2 | 2024 | 257 | 0.320 |
Why?
|
| Thrombosis | 2 | 2021 | 302 | 0.300 |
Why?
|
| Skin | 3 | 2018 | 581 | 0.300 |
Why?
|
| Multifactorial Inheritance | 2 | 2019 | 169 | 0.290 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 4 | 2023 | 55 | 0.290 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1114 | 0.290 |
Why?
|
| DNA-Binding Proteins | 4 | 2023 | 1241 | 0.280 |
Why?
|
| Sulfonylurea Compounds | 2 | 2024 | 65 | 0.280 |
Why?
|
| Cell Line, Tumor | 9 | 2023 | 2552 | 0.280 |
Why?
|
| Treatment Outcome | 12 | 2024 | 8203 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 196 | 0.270 |
Why?
|
| Receptor, ErbB-2 | 2 | 2019 | 245 | 0.260 |
Why?
|
| Biomarkers | 5 | 2024 | 1755 | 0.260 |
Why?
|
| Pyridones | 2 | 2023 | 55 | 0.260 |
Why?
|
| Young Adult | 14 | 2021 | 6288 | 0.260 |
Why?
|
| Precision Medicine | 3 | 2020 | 410 | 0.250 |
Why?
|
| HIV-1 | 3 | 2019 | 166 | 0.250 |
Why?
|
| Genes, BRCA1 | 3 | 2021 | 192 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 3657 | 0.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1176 | 0.240 |
Why?
|
| Male | 28 | 2024 | 42251 | 0.240 |
Why?
|
| Registries | 4 | 2024 | 778 | 0.240 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 9 | 0.240 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2024 | 35 | 0.230 |
Why?
|
| HIV Infections | 3 | 2019 | 835 | 0.230 |
Why?
|
| Neoadjuvant Therapy | 2 | 2024 | 373 | 0.230 |
Why?
|
| Electromyography | 1 | 2024 | 193 | 0.230 |
Why?
|
| Machado-Joseph Disease | 1 | 2023 | 8 | 0.220 |
Why?
|
| Hypoglycemic Agents | 2 | 2024 | 348 | 0.220 |
Why?
|
| Rivaroxaban | 1 | 2023 | 12 | 0.220 |
Why?
|
| Erythrocytes | 2 | 2021 | 254 | 0.220 |
Why?
|
| Hip Fractures | 1 | 2023 | 46 | 0.220 |
Why?
|
| Receptors, Estrogen | 3 | 2021 | 393 | 0.220 |
Why?
|
| Dabigatran | 1 | 2023 | 25 | 0.220 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 2752 | 0.220 |
Why?
|
| Diabetic Retinopathy | 1 | 2024 | 91 | 0.220 |
Why?
|
| DNA Repair Enzymes | 2 | 2020 | 55 | 0.220 |
Why?
|
| Biosensing Techniques | 1 | 2023 | 73 | 0.210 |
Why?
|
| Osteoporotic Fractures | 1 | 2023 | 43 | 0.210 |
Why?
|
| Risk Factors | 10 | 2023 | 5466 | 0.210 |
Why?
|
| Genetic Association Studies | 3 | 2020 | 294 | 0.210 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2024 | 187 | 0.210 |
Why?
|
| Breast Density | 2 | 2019 | 36 | 0.210 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2021 | 2399 | 0.210 |
Why?
|
| Warfarin | 1 | 2023 | 104 | 0.210 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2023 | 76 | 0.210 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 540 | 0.200 |
Why?
|
| Cohort Studies | 8 | 2021 | 2863 | 0.200 |
Why?
|
| Skilled Nursing Facilities | 1 | 2022 | 41 | 0.200 |
Why?
|
| Alcoholism | 1 | 2023 | 178 | 0.200 |
Why?
|
| Genome-Wide Association Study | 4 | 2021 | 1670 | 0.200 |
Why?
|
| Fractals | 1 | 2021 | 42 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2024 | 485 | 0.200 |
Why?
|
| Leuprolide | 1 | 2021 | 35 | 0.200 |
Why?
|
| Apraxias | 1 | 2021 | 3 | 0.200 |
Why?
|
| Research Design | 2 | 2023 | 597 | 0.200 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2018 | 73 | 0.190 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2021 | 9 | 0.190 |
Why?
|
| Abdominal Fat | 1 | 2021 | 13 | 0.190 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 502 | 0.190 |
Why?
|
| Mammography | 2 | 2022 | 471 | 0.190 |
Why?
|
| Administration, Oral | 1 | 2023 | 682 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1715 | 0.190 |
Why?
|
| Metformin | 1 | 2022 | 124 | 0.190 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 81 | 0.190 |
Why?
|
| MicroRNAs | 2 | 2016 | 551 | 0.190 |
Why?
|
| Elasticity | 1 | 2021 | 96 | 0.190 |
Why?
|
| Speech | 1 | 2021 | 85 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 156 | 0.180 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 18 | 0.180 |
Why?
|
| Oligopeptides | 1 | 2021 | 188 | 0.180 |
Why?
|
| Risk Assessment | 5 | 2023 | 2290 | 0.180 |
Why?
|
| Mutation, Missense | 4 | 2024 | 277 | 0.180 |
Why?
|
| Patient Positioning | 1 | 2021 | 65 | 0.180 |
Why?
|
| Neuroimaging | 1 | 2021 | 117 | 0.180 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 280 | 0.180 |
Why?
|
| Thromboembolism | 1 | 2021 | 120 | 0.180 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 373 | 0.180 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2019 | 3 | 0.180 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 136 | 0.170 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2019 | 25 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2021 | 73 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2023 | 426 | 0.170 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2016 | 25 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2016 | 45 | 0.170 |
Why?
|
| Viremia | 1 | 2019 | 49 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 443 | 0.170 |
Why?
|
| Quality Control | 2 | 2017 | 117 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2022 | 320 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 35 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2021 | 353 | 0.160 |
Why?
|
| Urinary Bladder | 1 | 2021 | 246 | 0.160 |
Why?
|
| Models, Statistical | 2 | 2016 | 575 | 0.160 |
Why?
|
| Trastuzumab | 1 | 2019 | 71 | 0.160 |
Why?
|
| Plasmids | 2 | 2016 | 291 | 0.160 |
Why?
|
| Caspase 8 | 1 | 2018 | 34 | 0.160 |
Why?
|
| HIV Protease | 1 | 2018 | 10 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2022 | 2014 | 0.160 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 397 | 0.160 |
Why?
|
| Emollients | 1 | 2018 | 3 | 0.160 |
Why?
|
| Anti-HIV Agents | 2 | 2013 | 155 | 0.150 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 1214 | 0.150 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 174 | 0.150 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2018 | 106 | 0.150 |
Why?
|
| Macrophages | 1 | 2021 | 571 | 0.150 |
Why?
|
| NADPH Oxidase 1 | 1 | 2017 | 2 | 0.150 |
Why?
|
| Patient Admission | 1 | 2018 | 114 | 0.150 |
Why?
|
| Interleukin-13 | 1 | 2017 | 38 | 0.150 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2017 | 11 | 0.150 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2017 | 16 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 185 | 0.140 |
Why?
|
| Hospitals | 1 | 2020 | 299 | 0.140 |
Why?
|
| Valine | 1 | 2017 | 62 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 112 | 0.140 |
Why?
|
| Cell Cycle Proteins | 2 | 2017 | 401 | 0.140 |
Why?
|
| Family | 1 | 2019 | 325 | 0.140 |
Why?
|
| Interleukin-4 | 1 | 2017 | 130 | 0.140 |
Why?
|
| Algorithms | 4 | 2019 | 1875 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 299 | 0.140 |
Why?
|
| Malassezia | 1 | 2016 | 2 | 0.140 |
Why?
|
| Disease Progression | 1 | 2021 | 1488 | 0.140 |
Why?
|
| Drug Therapy | 1 | 2017 | 70 | 0.140 |
Why?
|
| Dermatomycoses | 1 | 2016 | 9 | 0.140 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2017 | 93 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 65 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 3 | 0.140 |
Why?
|
| Nitrophenols | 1 | 2016 | 11 | 0.140 |
Why?
|
| Brain Ischemia | 1 | 2021 | 399 | 0.140 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2016 | 19 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 170 | 0.140 |
Why?
|
| Puberty | 1 | 2016 | 60 | 0.140 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 21 | 0.140 |
Why?
|
| Artificial Intelligence | 2 | 2011 | 322 | 0.130 |
Why?
|
| Retrospective Studies | 7 | 2024 | 9003 | 0.130 |
Why?
|
| Biphenyl Compounds | 1 | 2016 | 59 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 786 | 0.130 |
Why?
|
| Gene Expression | 2 | 2021 | 1310 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2020 | 548 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 205 | 0.130 |
Why?
|
| Reference Standards | 1 | 2016 | 144 | 0.130 |
Why?
|
| Phosphotransferases | 1 | 2015 | 65 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 412 | 0.130 |
Why?
|
| Isoindoles | 1 | 2015 | 14 | 0.130 |
Why?
|
| Medical History Taking | 3 | 2021 | 81 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 287 | 0.130 |
Why?
|
| Breast | 3 | 2022 | 292 | 0.130 |
Why?
|
| Inflammation | 1 | 2021 | 971 | 0.130 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 100 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 47 | 0.120 |
Why?
|
| Genotype | 4 | 2021 | 1848 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 267 | 0.120 |
Why?
|
| Histones | 1 | 2017 | 329 | 0.120 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 22 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 604 | 0.120 |
Why?
|
| Obesity | 1 | 2021 | 966 | 0.120 |
Why?
|
| Piperazines | 1 | 2016 | 283 | 0.120 |
Why?
|
| Benzamides | 1 | 2015 | 237 | 0.120 |
Why?
|
| Biological Specimen Banks | 1 | 2014 | 65 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 217 | 0.120 |
Why?
|
| Paclitaxel | 1 | 2016 | 479 | 0.120 |
Why?
|
| Sulfonamides | 1 | 2016 | 317 | 0.110 |
Why?
|
| United States | 6 | 2024 | 6955 | 0.110 |
Why?
|
| Sarcoma | 1 | 2015 | 220 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2018 | 695 | 0.110 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2013 | 3 | 0.110 |
Why?
|
| Odds Ratio | 3 | 2021 | 684 | 0.110 |
Why?
|
| Signal Transduction | 4 | 2018 | 3373 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1194 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1149 | 0.110 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 154 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 726 | 0.110 |
Why?
|
| Exome | 1 | 2013 | 127 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2021 | 771 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 833 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 573 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 665 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 1591 | 0.100 |
Why?
|
| Erythropoietin | 1 | 2012 | 88 | 0.100 |
Why?
|
| Adolescent | 6 | 2021 | 9237 | 0.100 |
Why?
|
| Heterozygote | 2 | 2023 | 373 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2013 | 138 | 0.100 |
Why?
|
| Microvessels | 2 | 2022 | 69 | 0.100 |
Why?
|
| Quinazolines | 1 | 2013 | 221 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 2552 | 0.100 |
Why?
|
| Apoptosis | 1 | 2018 | 1716 | 0.100 |
Why?
|
| Dermatitis, Atopic | 1 | 2012 | 55 | 0.100 |
Why?
|
| Probability | 1 | 2012 | 353 | 0.100 |
Why?
|
| Metagenome | 1 | 2012 | 104 | 0.090 |
Why?
|
| Logistic Models | 3 | 2021 | 1212 | 0.090 |
Why?
|
| Body Weight | 1 | 2012 | 452 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 3 | 2021 | 866 | 0.090 |
Why?
|
| ROC Curve | 2 | 2024 | 781 | 0.090 |
Why?
|
| Oxygen Consumption | 2 | 2021 | 243 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1768 | 0.090 |
Why?
|
| Models, Biological | 2 | 2019 | 1763 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2020 | 337 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 466 | 0.080 |
Why?
|
| Computer Simulation | 3 | 2020 | 1097 | 0.080 |
Why?
|
| Blood Glucose | 2 | 2024 | 836 | 0.080 |
Why?
|
| Age of Onset | 2 | 2021 | 312 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 576 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2018 | 1533 | 0.080 |
Why?
|
| DNA, Neoplasm | 2 | 2021 | 268 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1067 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 848 | 0.080 |
Why?
|
| Risk | 2 | 2021 | 657 | 0.080 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 2 | 2017 | 8 | 0.080 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2017 | 30 | 0.070 |
Why?
|
| RNA Helicases | 2 | 2017 | 35 | 0.070 |
Why?
|
| Virus Replication | 2 | 2019 | 321 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 783 | 0.070 |
Why?
|
| Internet | 2 | 2020 | 318 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2007 | 48 | 0.070 |
Why?
|
| Genomics | 3 | 2017 | 761 | 0.070 |
Why?
|
| Melanoma | 1 | 2011 | 467 | 0.070 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 415 | 0.070 |
Why?
|
| Decision Making | 1 | 2012 | 665 | 0.070 |
Why?
|
| Oxidative Stress | 2 | 2021 | 458 | 0.070 |
Why?
|
| Alleles | 2 | 2021 | 1135 | 0.070 |
Why?
|
| Workflow | 2 | 2017 | 80 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2021 | 865 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 1796 | 0.060 |
Why?
|
| Databases, Genetic | 2 | 2018 | 263 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 155 | 0.060 |
Why?
|
| Learning | 1 | 2007 | 285 | 0.060 |
Why?
|
| Germ Cells | 1 | 2024 | 130 | 0.050 |
Why?
|
| Computational Biology | 2 | 2017 | 542 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1940 | 0.050 |
Why?
|
| Sitagliptin Phosphate | 1 | 2022 | 2 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 4 | 0.050 |
Why?
|
| Insulin Glargine | 1 | 2022 | 9 | 0.050 |
Why?
|
| Age Factors | 2 | 2018 | 1867 | 0.050 |
Why?
|
| Motor Neurons | 1 | 2024 | 174 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 887 | 0.050 |
Why?
|
| Survival Rate | 2 | 2020 | 1889 | 0.050 |
Why?
|
| Bone Density | 1 | 2023 | 209 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2023 | 316 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 18 | 0.050 |
Why?
|
| Neurobiology | 1 | 2021 | 10 | 0.050 |
Why?
|
| Cerebellum | 1 | 2023 | 249 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2021 | 75 | 0.050 |
Why?
|
| Mitochondria, Muscle | 1 | 2021 | 26 | 0.050 |
Why?
|
| Anisotropy | 1 | 2021 | 63 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2021 | 34 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 250 | 0.050 |
Why?
|
| Supine Position | 1 | 2021 | 30 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2021 | 51 | 0.050 |
Why?
|
| Cell Count | 1 | 2021 | 200 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2021 | 71 | 0.050 |
Why?
|
| Everolimus | 1 | 2021 | 40 | 0.050 |
Why?
|
| tau Proteins | 1 | 2021 | 74 | 0.050 |
Why?
|
| Fibrin | 1 | 2021 | 86 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 63 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 37 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 273 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 783 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1650 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 142 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 192 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2021 | 225 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 412 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2021 | 111 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2023 | 341 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2021 | 150 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 304 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2019 | 67 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2015 | 2011 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2020 | 105 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 244 | 0.040 |
Why?
|
| Reference Values | 1 | 2020 | 661 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2021 | 477 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 168 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 68 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 336 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2020 | 187 | 0.040 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 42 | 0.040 |
Why?
|
| Child | 3 | 2016 | 7149 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2021 | 711 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 102 | 0.040 |
Why?
|
| Comamonadaceae | 1 | 2018 | 2 | 0.040 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 145 | 0.040 |
Why?
|
| Proteobacteria | 1 | 2018 | 6 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2657 | 0.040 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2018 | 56 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 90 | 0.040 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2018 | 20 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2022 | 351 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 207 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2018 | 77 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 46 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2020 | 448 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 1307 | 0.040 |
Why?
|
| Exercise | 1 | 2021 | 322 | 0.040 |
Why?
|
| Mice | 3 | 2019 | 11737 | 0.040 |
Why?
|
| MRE11 Homologue Protein | 1 | 2017 | 2 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2017 | 8 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 11 | 0.040 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2017 | 13 | 0.040 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2017 | 33 | 0.040 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2017 | 24 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 699 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2018 | 238 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 636 | 0.040 |
Why?
|
| Pandemics | 1 | 2023 | 771 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1240 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 802 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 58 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 108 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2017 | 41 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 112 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 607 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2018 | 94 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2017 | 66 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1714 | 0.030 |
Why?
|
| Sebaceous Glands | 1 | 2016 | 28 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 1108 | 0.030 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2016 | 11 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2018 | 685 | 0.030 |
Why?
|
| Aging | 1 | 2021 | 716 | 0.030 |
Why?
|
| Biodiversity | 1 | 2018 | 205 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 291 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3443 | 0.030 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2015 | 11 | 0.030 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2015 | 21 | 0.030 |
Why?
|
| Software | 1 | 2020 | 665 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2015 | 14 | 0.030 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2015 | 24 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 64 | 0.030 |
Why?
|
| Aurora Kinases | 1 | 2015 | 17 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 145 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 42 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2015 | 51 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 470 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 192 | 0.030 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 128 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 225 | 0.030 |
Why?
|
| beta Catenin | 1 | 2017 | 266 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2015 | 77 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 126 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 1239 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 107 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 282 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2015 | 122 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 115 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 371 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 272 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 490 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 386 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 732 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2015 | 183 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 186 | 0.030 |
Why?
|
| Bacteria | 1 | 2018 | 472 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 740 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 332 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 894 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 285 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 521 | 0.030 |
Why?
|
| Anorexia | 1 | 2013 | 30 | 0.030 |
Why?
|
| Drug Costs | 1 | 2013 | 63 | 0.030 |
Why?
|
| Neurons | 1 | 2021 | 1580 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 27317 | 0.030 |
Why?
|
| Staphylococcus | 1 | 2012 | 24 | 0.030 |
Why?
|
| Diarrhea | 1 | 2013 | 182 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2012 | 17 | 0.030 |
Why?
|
| Patient Selection | 1 | 2015 | 682 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 2327 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2013 | 235 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 2012 | 111 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 306 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 3147 | 0.020 |
Why?
|
| S Phase | 1 | 2011 | 63 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 248 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 2439 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 988 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 2001 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 308 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2011 | 103 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 247 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2012 | 232 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2011 | 253 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 443 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2012 | 335 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2011 | 814 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 269 | 0.020 |
Why?
|
| Hypertension | 1 | 2013 | 741 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 5320 | 0.020 |
Why?
|
| Quality of Life | 1 | 2014 | 1662 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 3717 | 0.020 |
Why?
|